Skip to main content
Questions about giving or our research? Call us — (800) 321-2873 Donor help Search

by
Blog
February 25, 2026

[vc_row][vc_column][vc_single_image image="67187" img_size="full" alignment="center" css=""][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=""]Researchers have found a promising biomarker that may help doctors predict which patients with extensive-stage small cell lung cancer (ES-SCLC) are most likely to respond to tarlatamab. This targeted immunotherapy is possible because of new insights into DLL3 biology, partially...

, , , ,

by
Blog
January 14, 2025

[vc_row][vc_column][vc_single_image image="62971" img_size="full" alignment="center" css=""][vc_column_text css=""]Two NFCR-supported researchers have recently published in the high-impact publication Nature Communications for their work on liquid biopsies and circulating tumor cells. Drs. Daniel A. Haber of Massachusetts General Hospital Cancer Center and Aditya Bardia of the University of California,...

, , , , , , , , ,

by
Blog
October 7, 2019

[vc_row][vc_column][vc_column_text] “HER2 is a gene that codes for a protein sitting on the cell surface and sending signals for the cell to grow and divide,” explains Dr. Daniel Haber, Director at Massachusetts General Hospital Cancer Center and Professor of Oncology at Harvard Medical School, about one...

,

by
Blog
October 24, 2018

[vc_row][vc_column width="1/4"][vc_single_image image="23417" img_size="medium" css=""][/vc_column][vc_column width="3/4"][vc_column_text css=""]A novel instrument for detecting cancer cells in the blood could lead to individualized cancer treatments for patients suffering metastasis. Developed by a Massachusetts General Hospital team led by Daniel Haber, M.D., Ph.D., a renowned cancer scientist supported by...

, , ,